How much revenue did Biocept generate this year?
Biocept has achieved a revenue of 21.91 M USD this year.
Biocept Revenue 2025
Biocept Revenue
21.91 M USD
Ticker
BIOC
ISIN
US09072V5012
WKN
A2QEQE
In 2025, Biocept's sales reached 21.91 M USD, a 231.86% difference from the 6.6 M USD sales recorded in the previous year.
The Biocept Revenue history
| YEAR | REVENUE (M USD) | GROSS MARGIN (%) |
|---|---|---|
| 2026e | 21.63 | -11,94 |
| 2025e | 21.91 | -11,79 |
| 2024e | 6.6 | -39,12 |
| 2023e | 2.53 | -102,22 |
| 2022 | 25.86 | -9,99 |
| 2021 | 61.25 | 38,34 |
| 2020 | 27.46 | 22,29 |
| 2019 | 5.53 | -98,55 |
| 2018 | 3.25 | -209,23 |
| 2017 | 5.07 | -84,42 |
| 2016 | 3.22 | -114,91 |
| 2015 | 0.61 | -654,10 |
| 2014 | 0.13 | -1569,23 |
| 2013 | 0.13 | -1692,31 |
| 2012 | 0.11 | -990,91 |
| 2011 | - | - |
Biocept Revenue, EBIT, Net Income
3 years
5 years
10 years
25 Years
Max
Loading chart...
Revenue
EBIT
Net Income
Details
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Biocept, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biocept from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biocept’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Biocept. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Biocept’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Biocept’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biocept’s growth potential.
Biocept Revenue, EBIT and net profit per share
| Date | Biocept Revenue | Biocept EBIT | Biocept Net Income |
|---|---|---|---|
| 2026e | 21.63 M undefined | -3.19 M undefined | -8.45 M undefined |
| 2025e | 21.91 M undefined | -17.27 M undefined | -15.41 M undefined |
| 2024e | 6.6 M undefined | -23.53 M undefined | -25.02 M undefined |
| 2023e | 2.53 M undefined | -24.44 M undefined | -100.64 M undefined |
| 2022 | 25.86 M undefined | -31.98 M undefined | -32.09 M undefined |
| 2021 | 61.25 M undefined | -2.41 M undefined | -2.82 M undefined |
| 2020 | 27.46 M undefined | -15.47 M undefined | -17.81 M undefined |
| 2019 | 5.53 M undefined | -23.06 M undefined | -25.26 M undefined |
| 2018 | 3.25 M undefined | -24.26 M undefined | -25.21 M undefined |
| 2017 | 5.07 M undefined | -21.17 M undefined | -21.61 M undefined |
| 2016 | 3.22 M undefined | -18.03 M undefined | -18.4 M undefined |
| 2015 | 610,000 undefined | -16.41 M undefined | -16.95 M undefined |
| 2014 | 130,000 undefined | -13.87 M undefined | -15.87 M undefined |
| 2013 | 130,000 undefined | -7.94 M undefined | -9.23 M undefined |
| 2012 | 110,000 undefined | -10.5 M undefined | -12.26 M undefined |
| 2011 | 0 undefined | -12.27 M undefined | -13.63 M undefined |
Biocept stock margins
The Biocept margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biocept. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biocept.
3 years
5 years
10 years
25 Years
Max
Loading chart...
Gross margin
EBIT margin
Profit margin
Details
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Biocept's sales revenue. A higher gross margin percentage indicates that the Biocept retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Biocept's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Biocept's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biocept's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biocept. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biocept's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Biocept Margin History
| Biocept Gross margin | Biocept Profit margin | Biocept EBIT margin | Biocept Profit margin |
|---|---|---|---|
| 2026e | -9.99 % | -14.74 % | -39.08 % |
| 2025e | -9.99 % | -78.84 % | -70.36 % |
| 2024e | -9.99 % | -356.39 % | -379.08 % |
| 2023e | -9.99 % | -967.47 % | -3,984.04 % |
| 2022 | -9.99 % | -123.69 % | -124.09 % |
| 2021 | 38.34 % | -3.93 % | -4.61 % |
| 2020 | 22.29 % | -56.34 % | -64.86 % |
| 2019 | -98.55 % | -417 % | -456.78 % |
| 2018 | -209.23 % | -746.46 % | -775.69 % |
| 2017 | -84.42 % | -417.55 % | -426.23 % |
| 2016 | -114.91 % | -559.94 % | -571.43 % |
| 2015 | -654.1 % | -2,690.16 % | -2,778.69 % |
| 2014 | -1,569.23 % | -10,669.23 % | -12,207.69 % |
| 2013 | -1,692.31 % | -6,107.69 % | -7,100 % |
| 2012 | -990.91 % | -9,545.45 % | -11,145.46 % |
| 2011 | -9.99 % | 0 % | 0 % |
Biocept Aktienanalyse
What does Biocept do?
Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding Biocept's Sales Figures
The sales figures of Biocept originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing Biocept’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize Biocept's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in Biocept’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about Biocept stock
How much was the turnover of the company Biocept compared to the previous year?
The revenue of Biocept has increased by 231.86% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of Biocept?
The revenue of Biocept is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of Biocept measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of Biocept so important for investors?
The revenue of Biocept is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does Biocept pay?
Over the past 12 months, Biocept paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biocept is expected to pay a dividend of 0 USD.
What is the dividend yield of Biocept?
The current dividend yield of Biocept is .
When does Biocept pay dividends?
Biocept pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Biocept?
Biocept paid dividends every year for the past 0 years.
What is the dividend of Biocept?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Biocept located?
Biocept is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biocept kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biocept from 9/26/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2025.
When did Biocept pay the last dividend?
The last dividend was paid out on 9/26/2025.
What was the dividend of Biocept in the year 2024?
In the year 2024, Biocept distributed 0 USD as dividends.
In which currency does Biocept pay out the dividend?
The dividends of Biocept are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biocept
Our stock analysis for Biocept Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biocept Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
